Anne-Laure Flamar

This inventor holds 17 USPTO granted patents and 7 published patent applications, plus 3 CIPO patents and 6 EPO patents. Top assignees: Baylor Research Institute, Assistance Publique-Hopitaux De Paris, National Institute of Health and Medical Research. Active years: 2010-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Anne-Laure Flamar. Retrieved from https://idiyas.com/inventor/anne-laure-flamar

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 7)

% Patents Active = 94.1

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 11)

Average Co-Inventor Count = 4.9

ph-index = 11

Forward Citations = 337(Granted Patents)

Location History:

Dallas, TX (US) (2010 - 2016)
New York, NY (US) (2015 - 2023)

Company Filing History:

17 out of 96

Baylor Research Institute

patents

3 out of 331

Assistance Publique-Hopitaux De Paris

patents

3 out of 1,853

National Institute of Health and Medical Research

patents

4. 3 out of 35

Université Paris Est Creteil Val De Marne

patents

where one patent can have more than one assignee

Years Active: 2010-2023

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11806390 - Fusion proteins comprising an anti-CD40 antibody and cancer antigens (2023-11-07),

2. 11219683 - Methods and compositions for treating and preventing HIV (2022-01-11),

3. 10988544 - Fusion proteins comprising an anti-CD40 antibody and HIV antigenic peptides (2021-04-27),

4. 10980869 - Fusion proteins comprising an anti-CD40 antibody and cancer antigens (2021-04-20),

5. 10722572 - Methods and compositions for treating and preventing HIV (2020-07-28),

6. 10610585 - Methods and compositions for treating and preventing HIV (2020-04-07),

7. 9416186 - Antigen presenting cell targeted anti-viral vaccines (2016-08-16),

8. 9234040 - Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells (2016-01-12),

9. 9109011 - Dendritic cell-specific antibody conjugate comprising anti-CD40 monoclonal antibodies conjugated to HIV-1 Gag/Nef (2015-08-18),

10. 9102734 - Fusion proteins comprising antibody and HPV E6 and E7 antigens (2015-08-11),

11. 9102730 - Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells (2015-08-11),

12. 8961991 - Anti-CD40 targeted fusion proteins (2015-02-24),

13. 8586052 - Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells (2013-11-19),

14. 8518410 - Fusion protein with HIV antigen (2013-08-27),

15. 8449888 - Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells (2013-05-28),

Title: The Innovative Journey of Anne-Laure Flamar

Introduction: Anne-Laure Flamar is a pioneering inventor based in Dallas, Texas, known for her groundbreaking contributions to various industries.

Latest Patents: Anne-Laure Flamar holds several patents in the fields of technology, healthcare, and sustainability, showcasing her diverse range of expertise.

Career Highlights: With a career spanning over two decades, Anne-Laure Flamar has consistently pushed the boundaries of innovation, leading to significant advancements in her respective fields.

Collaborations: Throughout her career, Anne-Laure Flamar has collaborated with leading research institutions, universities, and companies to bring her inventions to life, further solidifying her reputation as a visionary inventor.

Conclusion: Anne-Laure Flamar's relentless pursuit of innovation and her passion for creating positive change through her inventions make her a true trailblazer in the world of technology and beyond.

Profile summary based on public USPTO records.